GB2127024A - Modified proteins and process for the production thereof - Google Patents
Modified proteins and process for the production thereof Download PDFInfo
- Publication number
- GB2127024A GB2127024A GB08314851A GB8314851A GB2127024A GB 2127024 A GB2127024 A GB 2127024A GB 08314851 A GB08314851 A GB 08314851A GB 8314851 A GB8314851 A GB 8314851A GB 2127024 A GB2127024 A GB 2127024A
- Authority
- GB
- United Kingdom
- Prior art keywords
- protein
- enzyme
- denatured
- native
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 85
- 108091005573 modified proteins Proteins 0.000 title claims abstract description 76
- 102000035118 modified proteins Human genes 0.000 title claims abstract description 76
- 230000008569 process Effects 0.000 title claims abstract description 53
- 238000004519 manufacturing process Methods 0.000 title abstract description 6
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 204
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 204
- 102000004190 Enzymes Human genes 0.000 claims abstract description 85
- 108090000790 Enzymes Proteins 0.000 claims abstract description 85
- 239000003112 inhibitor Substances 0.000 claims abstract description 37
- 229940121649 protein inhibitor Drugs 0.000 claims abstract description 8
- 239000012268 protein inhibitor Substances 0.000 claims abstract description 8
- 239000000758 substrate Substances 0.000 claims description 48
- 239000003795 chemical substances by application Substances 0.000 claims description 21
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 15
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 claims description 11
- 238000004132 cross linking Methods 0.000 claims description 10
- 239000003431 cross linking reagent Substances 0.000 claims description 10
- 239000007864 aqueous solution Substances 0.000 claims description 9
- 239000004202 carbamide Substances 0.000 claims description 9
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea group Chemical group NC(=O)N XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 7
- 229960000789 guanidine hydrochloride Drugs 0.000 claims description 6
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical group [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 claims description 6
- 150000007522 mineralic acids Chemical group 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical group O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims 4
- 150000007524 organic acids Chemical group 0.000 claims 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims 2
- 235000011054 acetic acid Nutrition 0.000 claims 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims 2
- 235000015165 citric acid Nutrition 0.000 claims 2
- 235000019253 formic acid Nutrition 0.000 claims 2
- 229910017604 nitric acid Inorganic materials 0.000 claims 2
- 235000019260 propionic acid Nutrition 0.000 claims 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims 2
- 230000003197 catalytic effect Effects 0.000 abstract description 26
- 230000002255 enzymatic effect Effects 0.000 abstract description 14
- 229940088598 enzyme Drugs 0.000 description 79
- 239000000243 solution Substances 0.000 description 78
- 239000000523 sample Substances 0.000 description 57
- 108090000371 Esterases Proteins 0.000 description 37
- 238000003556 assay Methods 0.000 description 34
- 230000000694 effects Effects 0.000 description 33
- 239000000872 buffer Substances 0.000 description 26
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 24
- 238000000502 dialysis Methods 0.000 description 22
- 239000007983 Tris buffer Substances 0.000 description 21
- 229940098773 bovine serum albumin Drugs 0.000 description 21
- 238000004925 denaturation Methods 0.000 description 20
- 230000036425 denaturation Effects 0.000 description 20
- APJYDQYYACXCRM-UHFFFAOYSA-N tryptamine Chemical compound C1=CC=C2C(CCN)=CNC2=C1 APJYDQYYACXCRM-UHFFFAOYSA-N 0.000 description 20
- 108010083644 Ribonucleases Proteins 0.000 description 19
- 102000006382 Ribonucleases Human genes 0.000 description 19
- 239000000126 substance Substances 0.000 description 19
- 238000006243 chemical reaction Methods 0.000 description 16
- 239000007858 starting material Substances 0.000 description 16
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 16
- 238000004128 high performance liquid chromatography Methods 0.000 description 14
- 238000002347 injection Methods 0.000 description 14
- 239000007924 injection Substances 0.000 description 14
- 239000000463 material Substances 0.000 description 14
- 238000003756 stirring Methods 0.000 description 14
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical group O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 13
- 230000008859 change Effects 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 12
- 239000013584 assay control Substances 0.000 description 12
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 11
- 229920005654 Sephadex Polymers 0.000 description 10
- 239000012507 Sephadex™ Substances 0.000 description 10
- 239000012488 sample solution Substances 0.000 description 10
- 230000008033 biological extinction Effects 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 7
- 108010024636 Glutathione Proteins 0.000 description 7
- 238000002835 absorbance Methods 0.000 description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 7
- 229910001220 stainless steel Inorganic materials 0.000 description 7
- 239000010935 stainless steel Substances 0.000 description 7
- 238000007619 statistical method Methods 0.000 description 7
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 6
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 6
- 229960001484 edetic acid Drugs 0.000 description 6
- 238000002523 gelfiltration Methods 0.000 description 6
- 239000006225 natural substrate Substances 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 239000000377 silicon dioxide Substances 0.000 description 6
- 229960004799 tryptophan Drugs 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 230000007717 exclusion Effects 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 5
- 239000004366 Glucose oxidase Substances 0.000 description 4
- 108010015776 Glucose oxidase Proteins 0.000 description 4
- 101710163270 Nuclease Proteins 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 238000004364 calculation method Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000002532 enzyme inhibitor Substances 0.000 description 4
- 229940125532 enzyme inhibitor Drugs 0.000 description 4
- 229940116332 glucose oxidase Drugs 0.000 description 4
- 235000019420 glucose oxidase Nutrition 0.000 description 4
- 229960003180 glutathione Drugs 0.000 description 4
- 230000000977 initiatory effect Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 108010053070 Glutathione Disulfide Proteins 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 239000008351 acetate buffer Substances 0.000 description 3
- -1 amino acid esters Chemical class 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- KCUNTYMNJVXYKZ-JTQLQIEISA-N methyl (2s)-2-amino-3-(1h-indol-3-yl)propanoate Chemical compound C1=CC=C2C(C[C@H](N)C(=O)OC)=CNC2=C1 KCUNTYMNJVXYKZ-JTQLQIEISA-N 0.000 description 3
- 150000004702 methyl esters Chemical class 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000012299 nitrogen atmosphere Substances 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 3
- 230000009897 systematic effect Effects 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 102100031673 Corneodesmosin Human genes 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 108090000854 Oxidoreductases Proteins 0.000 description 2
- 102000004316 Oxidoreductases Human genes 0.000 description 2
- 108090000526 Papain Proteins 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 229940096437 Protein S Drugs 0.000 description 2
- 108090000992 Transferases Proteins 0.000 description 2
- 102000004357 Transferases Human genes 0.000 description 2
- 108010031318 Vitronectin Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000012888 bovine serum Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 108010088756 des(121-124)-ribonuclease Proteins 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- YVECGMZCTULTIS-PBXRRBTRSA-N glucal Chemical compound OC[C@H]1OC=C[C@@H](O)[C@@H]1O YVECGMZCTULTIS-PBXRRBTRSA-N 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 108010043052 lysine monooxygenase Proteins 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000002572 peristaltic effect Effects 0.000 description 2
- 238000000053 physical method Methods 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000004153 renaturation Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 229960001322 trypsin Drugs 0.000 description 2
- 238000002211 ultraviolet spectrum Methods 0.000 description 2
- WFIYPADYPQQLNN-UHFFFAOYSA-N 2-[2-(4-bromopyrazol-1-yl)ethyl]isoindole-1,3-dione Chemical compound C1=C(Br)C=NN1CCN1C(=O)C2=CC=CC=C2C1=O WFIYPADYPQQLNN-UHFFFAOYSA-N 0.000 description 1
- MCLXKFUCPVGZEN-UHFFFAOYSA-N 4,6-dichloro-1,3,5-triazin-2-amine Chemical compound NC1=NC(Cl)=NC(Cl)=N1 MCLXKFUCPVGZEN-UHFFFAOYSA-N 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 108090000531 Amidohydrolases Proteins 0.000 description 1
- 102000004092 Amidohydrolases Human genes 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 102000004452 Arginase Human genes 0.000 description 1
- 108700024123 Arginases Proteins 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108010004032 Bromelains Proteins 0.000 description 1
- 206010007733 Catabolic state Diseases 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 108010059892 Cellulase Proteins 0.000 description 1
- 102000003914 Cholinesterases Human genes 0.000 description 1
- 108090000322 Cholinesterases Proteins 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 1
- 229940122601 Esterase inhibitor Drugs 0.000 description 1
- 108090000270 Ficain Proteins 0.000 description 1
- 102000030789 Histidine Ammonia-Lyase Human genes 0.000 description 1
- 108700006308 Histidine ammonia-lyases Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000003820 Lipoxygenases Human genes 0.000 description 1
- 108090000128 Lipoxygenases Proteins 0.000 description 1
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 241001442654 Percnon planissimum Species 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 108010059820 Polygalacturonase Proteins 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 108010028144 alpha-Glucosidases Proteins 0.000 description 1
- 102000016679 alpha-Glucosidases Human genes 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical compound [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000003592 biomimetic effect Effects 0.000 description 1
- 108010089934 carbohydrase Proteins 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 229940106157 cellulase Drugs 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 229940048961 cholinesterase Drugs 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 238000002983 circular dichroism Methods 0.000 description 1
- 238000001142 circular dichroism spectrum Methods 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000012954 diazonium Substances 0.000 description 1
- 150000001989 diazonium salts Chemical class 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000009144 enzymatic modification Effects 0.000 description 1
- 239000002329 esterase inhibitor Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 108010093305 exopolygalacturonase Proteins 0.000 description 1
- 235000019985 fermented beverage Nutrition 0.000 description 1
- 108091005899 fibrous proteins Proteins 0.000 description 1
- 102000034240 fibrous proteins Human genes 0.000 description 1
- POTUGHMKJGOKRI-UHFFFAOYSA-N ficin Chemical compound FI=CI=N POTUGHMKJGOKRI-UHFFFAOYSA-N 0.000 description 1
- 235000019836 ficin Nutrition 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005428 food component Substances 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 102000034238 globular proteins Human genes 0.000 description 1
- 108091005896 globular proteins Proteins 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 108010059345 keratinase Proteins 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000011034 membrane dialysis Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000007833 oxidative deamination reaction Methods 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 125000000405 phenylalanyl group Chemical group 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
Abstract
Disclosed is a modified enzyme- like protein and a process for the production thereof. In one embodiment, a native protein is grossly denatured. Subsequently, the grossly denatured protein is partially renatured to form a partially denatured protein. The partially denatured protein is contacted with an inhibitor of a model enzyme whose biological catalytic activity is to be modelled. The partially denatured native protein in the protein-inhibitor complex is cross-linked to produce a new enzyme-like modified protein. The enzyme-like modified protein shows the enzymatic catalytic behaviour characteristics of the model enzyme.
Description
SPECIFICATION
Modified proteins and process for the production thereof
Background of the invention 1. Field of the invention
Proteins are biologically synthesized macromolecules having various role in living systems. Enzymes are particular varieties of biologically-active proteins which catalyze specific reactions. Presently, enzyme technology is used in many areas in industry and research such as, for example, medical research, food processing and preservation, the production of fermented beverages, the production of pharmaceuticals and the analytical determination of the concentration of various metabolities and food components by analytical enzyme techniques.
Enzymes are highly specific in their biological activity and generally catalyze a particular reaction at a very high rate compared to the corresponding reaction occurring at room temperature without biological catalysis. One enzyme may show catalytic activity with respect to a number of substrates upon which it can act.
Accordingly, a given enzyme may catalyze the synthesis or degradation of more than one substrate. Some proteins which are not considered classical enzymes, such as bovine serum albumin, show very limited catalytic activity with respect to one or more substrates.
Many enzymes are found in nature in very small quantites. Accordingly, their isolation, purification and use is limited to a small scale operation in view of the expense and time needed to isolate them in a useful form.
Some enzymes occur in nature in relatively
large quantities and are relatively easy to isolate, purify and use. Unfortunately, due to the precise catalytic behavior of the enzymes, the enzymes available in large quantities can only catalyze certain select reactions.
Much effort has been directed recently toward the synthesis of synthetic biological catalysts which exhibit enzymatic behaviour similar to the enzymatic behaviour exhibited by native enzymes which are either scarce or expensive to isolate.
Further, some attempts have been made to
modify native enzymes to change their enzymatic
specificity so that they may function to catalyze a
reaction which they previously could not catalyze.
2. Description of the references
One technique known to achieve enzyme
behaviour to catalyze a specific desired reaction is
the synthesis of so-called enzyme model
molecules. For example, low molecular weight
compounds may be covalently bonded to
functional groups which exhibit the activity of the
active site of an enzyme. Examples of such
preparations are described in the publications:
Breslow, R.,Advances in Chemistry Series, R. F.
Grould, Ed., American Chemical Society,
Washington, D.C. 21-43 (1971) and Tang, C. C.;
Davalian, D.; Haung. P. and Breslow, R.,J.Amer.
Chem. Soc., 100, 3918(1978)and and Breslow, R.,
Doherty, J., Guillot, G. and Lipsey, C., J. Amer.
Chem. Soc., 100,3227(1978).
Another technique involves the use of a synthetic polymer matrix which is modifed along its backbone to provide functional groups which exhibit the function of the active site of a given enzyme. Examples of such techniques can be found in the following articles: Wulff, G. and
Schulza, l., Israel J. Chem. 17,291(1978) and
Suh, J. and Klotz, I. M., Bioorganic Chemistry, 6, 165(1977).
Another technique involves the attachment of a new chemical moiety to a native enzyme near the active site of the enzyme to attempt to cause such enzyme to react with a different catalytic activity. One example of this is the conversion of papain, a proteolytic enzyme to an oxidase type enzyme by the covalent attachment of a flavin near the active site of the native papain enzyme, as illustrated in the articles: Levine, H. L. and
Kaiser, E. T., J. Amer. Chem. Soc., 100, 7670 (1978), Kaiser, E. T., et al,Adv. In Chemistry
Series, No. 191, Biomimetic Chemistry, page 35, 1980; and Otsuki, T.; Nakagawa, Y. and Kaiser, E.
T., J. C. S. Chem. Comm., 11,457 (1978). Other examples of such enzymatic modification may be found in the article: Wilson, M. E. and Whitesides,
G. M., J. Amer. Chem. Soc., 100, 306 (1978).
Still another attempt to change enzyme specificity is the immobilization of a native enzyme into a gel matrix. For example, trypsin enzyme has been immobilized in polyacrylamide gel. The polyacrylamide gel allows amino acid esters to diffuse through the gel matrix to react with the enzyme but will not allow larger proteins to diffuse through. Thus, the enzyme specificity is changed by eliminating access of one of the substrate molecules to the enzyme.
The immobilization of native enzymes is well established in the art. Also, examples of enzyme specificity changes by immobilization are known in the art. Both immobilization and enzyme specificity changes are described in the Kirk
Othmer Encyclopedia of Chemical Technology, 3 Ed., 9, 148 (1980) published by Wiley and Son.
Inc.
Two other methods relating to enzyme immobilization are disclosed in U.S. Patents 3,802,997 and 3,930,950. In U.S. Patent 3,802,997, a method of stabilizing enzymes by bonding the enzymes to inorganic carriers, in the presence of their substrates, whereby the enzyme is immobilized, is disclosed. In U.S. Patent 3,930,950, a method of enzyme immobilization is disclosed wherein an active support member is provided which is capable of reacting with an enzyme to become chemically bonded thereto.
Subsequently, the active support is contacted with an enzyme-substrate complex which has been formed by mixing together an enzyme and a specific substrate, while minimizing the transformation of substrate to product. Thus, the enzyme component of the complex becomes chemically bonded to the support member.
Also, it has been known that a native lysine mono-oxygenase can be reacted to block the sulfhydryl groups on the enzyme. When the specific enzyme lysine mono-oxygenase is so treated, it shows new catalytic activity toward amino acids and catalyses oxidative deamination instead of its natural oxygenative decarboxylation.
However, the reporters cannot account for the modified behaviour. See the article by Yamauchi,
T.; Yamamoto, S. and Hayaishi, O., in The Journal ofBiological Chemistry, 248, 10, 3750-3752 (1973). Also, it has been reported that by reacting a native enzyme, for example. trypsin, with its natural inhibitor, and subsequently cross-linking the enzyme, its activity with respect to its natural substrates can be modified. See the article by
Beaven, G. H. and Gratzer, W. B. in Int. J. Peptide Res.,5,215-18(1973).
Also, synthetic proteins have been synthesized by the anchoring of an amino acid residue on a solid support and subsequently adding amino acid residues one after another.
Further, semisynthetic proteins have been synthesized by a method wherein a native protein is subjected to limited hydrolysis to produce protein fragments. The fragments of the native protein are then subjected to a process whereby one or more amino acid residues are added or removed from the fragments to form modified fragments. The resultant modified fragments are then reattached to form the semisynthetic protein with an altered amino acid residue composition.
Examples of the synthetic and semisynthetic protein technologies cited immediately above are found in the book Semisynthetic Proteins by R. E.
Offord, published by John Wiley and Sons Ltd., copyrighted in 1980.
While these techniques are suitable for many applications, a need exists for a simple, efficient, economical and systematic method for chemically modifying an inexpensive and commerciaily available native protein to produce an enzyme-like modified protein. The protein can show a catalytic enzymatic activity with respect to a desired chemical reaction which was not previously a commercially-useful reaction catalyzed by the native enzyme and which new reaction can be predetermined in a systematic fashion. The methods disclosed in the above-disclosed references simply subject an enzyme to a set of conditions and attempt to eludicate its behavior.
They fail to provide a systematic method to modify protein characteristics.
Summary of the invention
The present invention achieves an enzyme-like modified protein by converting a naturally occurring so-called native protein to an enzymelike modified protein exhibiting different characteristics that the native protein starting material.
In one embodiment of the invention, a native protein is grossly denatured by contacting the native protein with a denaturing agent, for a time and at a concentration sufficient to cause essentially gross protein denaturation. Next, the grossly denatured protein is subjected to conditions that cause the partial renaturation of the protein to produce a partially denatured native protein. The partially denatured protein is contacted with an inhibitor of a model enzyme, whose catalytic activity is to be modeled, to form a partially denatured protein-inhibitor complex.
The partially denatured protein in the complex is next cross-linked to produce a new enzyme-like modified protein.
Subsequently, the model enzyme inhibitor and any excess cross-linking agent are removed from the newly formed enzyme-like modified protein to yield a functional, stable, analogue to the model enzyme. The enzyme-like modified protein thusly produced exhibits the catalytic activity characteristics of the model enzyme.
Detailed description of the invention
In attaining the advantages of the present invention, it has been discovered that a protein can be modified from its native conformation to a modified conformation by practicing the process of the present invention. The new conformational state defines an enzyme-like modified protein.
As used herein, the word "enzyme" is defined as a protein which has well-known catalytic activity toward specific substrates. The term "protein" as used herein is defined as generally accepted in the art, to wit, a polypeptide formed of amino acids to yield a biological molecule.
The process of the present invention comprises chemically modifying a native protein from one conformation, its natural or native state, to a second conformation, a new modified state. The process produces a new, enzyme-like modified protein which is produced to yield a stable, new enzyme-like modified protein which models one or more of the enzymatic activity characteristics of the selected model enzyme.
In the preferred embodiment of the invention, a native protein is selected which is to be chemically modified to produce a new enzymelike modified protein analogue of a desired model enzyme. The process of the present invention converts the soluble native protein, which does not possess the desired catalytic activity, namely the enzymatic catalysis behaviour of the model enzyme, into a stable, enzyme-like modified protein which mimics or copies the biological catalytic activity characteristics of the model enzyme.
A preferred way of carrying out the novel process of the present invention for chemically modifying a native protein to produce a predetermined enzyme-like modified protein comprises the steps of: grossly denaturing the native protein by contacting the native protein with a denaturing agent, for a time and at a concentration sufficient to grossly denature the native protein; partially renaturing the grossly denatured protein to produce an only partially denaturd protein by contacting the grossly denatured protein with reagents or process conditions sufficient to partially renature or refold the protein; contacting the resultant only partially denatured protein with an inhibitor for a selected model enzyme, for a time sufficient and a temperature sufficient, to produce a partially denatured protein-inhibitor complex and subsequently cross-linking the partially denatured protein in the complex to form the new, stable enzyme-like modified protein by contacting the partially denatured protein with a cross-linking agent. Any excess cross-linking agent and the model enzyme inhibitor are removed from the
newly created enzyme-like modified protein to isolate the new, catalytically active enzyme-like modified protein product.
While in the preferred embodiment, a nonenzymatic native protein starting materials or so-called host protein is converted into a catalytically active, enzyme-like modifed protein, the conversion of any native protein to an enzyme-like modified protein analogue of a model enzyme is contemplated herein. Generally, native or host proteins which are most readily available for conversion into an enzyme-like modified form are nonenzymatic proteins, like bovine serum albumin. Preferably, the native protein starting material is selected because it is available in reasonably pure form, in commercially useful quantities, at reasonable unit costs. However, as exemplified hereinafter, any protein can be used as the native protein starting material, either enzymatic or nonenzymatic proteins.Typically nonenzymatic protens, like bovine serum alumin, are available in pure form, in large quantities at lower cost than enzymatic proteins, and are thus preferred starting materials.
As disclosed above, the starting material native protein is grossly denatured or unfolded to essentially destroy its native three dimensional chemical structure. Next, to achieve a protein structure which is capable of binding inhibitor, although not the native structure, the grossly denatured protein is partially refolded to produce a partially denatured protein. The partially denatured protein has neither the chemical structure, so-called conformation, of its parent, the native protein starting material, or of the grossly denatured protein it was produced immediately from. While not being bound by any theory, it is believed that the gross denaturation of the native protein starting material and then only partial refolding thereof allow for potential new inhibitor binding sites to be generated.Thus, different sites are generated than would be available if the native protein itself were partially denatured without going through a gross denaturation step prior to contacting the protein with the inhibitor.
As used herein, the phrase "grossly denatured" is defined as generally accepted in the art, to wit, a major change from the native state which causes the protein to become essentially completely unfolded. In the grossly denatured state, the protein lacks both secondary and tertiary structure and resembles a random coil.
The grossly denatured state can be determined by comparison of physical measurements of the grossly denatured protein to those of a model random coil. Examples of such physical measurements for the determination of gross denaturation are viscosity, circular dichroism, sedimentation coefficient and ultraviolet spectra.
Within the defination of grossly denatured proteins are some protein whcih may contain a trace of residual secondary and/or tertiary structure. Such traces of residual structure do not adversely effect the operation of the present invention.
The characteristics of grossly denatured proteins are well-known in the art. For example, when using a viscosity measurement to monitor protein denaturation, the viscosity of a globular protein generally goes up during the unfolding process. On the other hand, the viscosity of fibrous protein is quite large in the native state and may either increase or decrease upon unfolding. Such measurement changes during denaturation are well listed in the iiterature as described hereinafter. Unfolding can also be monitored by the change in ultraviolet spectra.
The major change in spectra occurs because of the transfer of phenylalanyl, trypyl, and tryptophyl side chains from the protein interior to the solvent environment during denaturation. Generally the molar absorptivity will decrease at some wavelengths while increasing at others due to the shift in the absorption bands. The gross denaturation of protein structure dramatically changes the optical rotation and circular dichroism spectra. The exact nature of the changes relate to the secondary and tertiary structure of the native protein. These physical parameters, used to determine gross denaturation, as well as many others, can be
monitored to determine when a protein is grossly denatured as described in many papers or protein denaturation such as: Charles Tandford,Advances in Protein Chemistry, 23, (1968).
Several review articles describe the process of gross denaturation and the criteria for demonstrating gross denaturation in terms
generally accepted in the art and used according
to this invention, namely, the following articles,
CharlesTanford,Adv. Protein Chemistry, 23, 121
(1968); P. L. Privalov,Adv. Protein Chemistry, 33,
167 (1979); and C. B. Anfinsen, Science, 181,
223 (1973).
The preferred methods of protein gross
denaturation according to the invention are as
follows.
Gross denaturation of a native protein starting
material can be achieved fro most proteins by the
use of guanidine hydrochloride (GuHCI). Gross
protein denaturation is usually complete by
concentrations of from 6 to 8 M GuHCI. In many
instances, urea can be substituted fro GuHCI in a
concentration of about 8 M to achieve gross
denaturation. Gross denaturation can also be achived by raising the temperature until the well recognized unfolding transition takes place.
Moreover extremes of acidic or basic conditions alone or in combination with temperature can be used. Generally, for most proteins a temperature on the order of 50--700C. is sufficient to grossly denature the native protein starting material.
Suitable acids for gross denaturation include acetic, formic, propionic and citric, while suitable bases include sodium and potassium hydroxide.
Suitable inorganic acids as denaturing agents include nitric, phosphoric, sulfuric and hydrochloric.
When the gross denaturing conditions are reduced the protein molecules becomes partially renatured. This partially renatured state may consist of protein molecules that remain nearly totally denatured mixed with other molecules are nearly completely refolded. In the alternative, nearly all protein molecules are nearly completely refolded. In the alternative, nearly all protein molecules could be partially and nearly equally refolded. The exact physical state of the partially renatured protein is not critical to the present invention. The partially renatured protein state will be recognized by the changes in physical parameters which indicate that the protein is no longer a random coil but contains considerable secondary and tertiary structure.The partially renatured state, however, lacks the highly ordered structure of the native protein state and is believed to afford different potential sites for inhibitor binding than a partially denatured native protein. The partially renatured protein is believed to offer different binding sites for the inhibitor since it has been completely structurally rearranged due to the gross denaturation step.
The grossly denatured protein can be partially renatured to offer new sites, not previously offered in a particular denatured native protein.
for inhibitor binding.
The partial renaturation of grossly denatured proteins is well known in the art and discussed in detail in the following references:
L. G. Chavez, Jr. and H. A. Scheraga,
Biochemistry, (1980), 19,996-1004; H.
Taniuchi and C. B. Anfinsin (1968), J. Biol. Chem., 243, 4778; H. Taniuchi and C. B. Anfinsin (1969),
J, Biol. Chem., 244, 3864; M. I. Kanehisa and T.
Y. Tsong, Biopolymers, 18, 2913-2928 (1979);
E. W. Miles, K. Yutani, and K. Ogasachara,
Biochemistry, 21, 11, (1982) and D. B. Witlanfer,
Adv. Protein Chemistry, 34, 61 (1981).
After the protein is partially renatured it is contacted with an inhibitor of a model enzyme whose catalytic activity is to be mimicked.
As used herein, the term "inhibitor" means any compound with sufficient structural similarity to the natural substrate of a model enzyme to serve as a template for the catalytic site of the enzymelike modified protein. In the preferred embodiment of the preparation of an enzyme-like modified protein, the inhibitor is any of the known classical inhibitors for a given model enzyme.
However, as used herein "inhibitor" can include any molecule with sufficient structural similarity to the classical inhibitor to preserve an inhibitor like site on the modified protein. The natural substrate of the model enzyme can act as the inhibitor or template for the modified protein in many cases. Inhibitors are generally not degraded by the enzyme, as are substrates, and serve to more readily preserve a catalytic site than the natural substrate. One example of the structural similarity of an enzyme inhibitor and the natural substrate of an enzyme is the case of glucose oxidase. Glucose is the natural substrate of glucose oxidase while D-glucal is the inhibitor for glucose oxidase. Glucose and D-glucal are very structurally similar.
In the preferred embodiment, after the partially renatured protein has been contacted with the
inhibitor for a time sufficient and at a temperature sufficient to form the protein-inhibitor complex and partially renatured protein portion of the complex is cross-linked to stabilize the new structure.
As used herein, the term "cross-linking" means the formation of covalent bonds between reactive sites on a protein. Generally, protein cross-linking is accomplished by the use of multifunctional reagents such as glutaraldehyde. Other examples of suitable cross-linking reagents to effect the cross-linking of a protein are: 2-amino-4, 6dichloro-s-triazine; diazonium salts; Nhydroxysuccinamide; p-benzyolyazide and those reagents disclosed in the following references:
Wold, F., Methods Enzymol, 11, edited by C. H. W.
Hirs, C. H. W., Academic Press, 1967, 617;
Fasold, H. et al.,Augen. Chem. Int. Ed. Engiv 10, 795, 197 and Keyes, M. H., in the Kirk-Othmer Encyclopedia Chemical Technology, 9, 3rd Ed., 1980, J. Wiley 8 Sons, Inc., 148-1 72. Crosslinking may also be achieved by disulphide rearrangement.
One preferred process to grossly denature a native protein starting material with betamercaptoethanol is the following. The native protein is admixed with beta-mercaptoethanol in a molar ratio of about 1000 units of betamercaptoethanol to one unit of protein. After treatment with beta-mercaptoethanol, at neutral pH, for one to several hours, quanidine hydrochloric is added to a concentration of 6 M.
These conditions are sufficient to totally denature most proteins. Preferably, the concentration of protein and pH should be such that part or most of the protein remains in solution. The betamercaptoethanol cleaves disulphide bridges and facilitates the gross denaturation of the protein by assisting in structure degradation.
In the preferred embodiment of the invention, a native protein or host protein showing little or no catalytic activity with respect to a selected substrate is converted chemically by the process of the present invention into an enzyme-like modified protein analogue of a model enzyme.
Many enzymes are susceptible to modeling or mimicking by the present process to produce their enzyme-like modified protein analogues from selected native protein starting materials.
Examples of such model enzymes which are subject to enzyme-like modified protein analogue production are hydrolytic enzymes, redox enzymes and transferase enzymes. By way of example: The first group, hydrolytic enzymes include proteolytic enzymes which hydrolyze proteins, e.g., papa in, ficin, pepsin, trypsin, chymotrypsin, bromelin, keratinase; carbohydrases which hydrolyze carbohydrates, e.g., cellulase, amylase, maltase, pectinase, chitanase; esterases which hydrolyze esters, e.g.
lipase, cholinesterase, lecithinase, alkaline and acid phosphateases; nucleases which hydrolyze nucleic acid, e.g. ribonuclease, deoxyribonuclease; and amidases which hydrolyze amines, e.g., arginase, asparaginase, glutinase, histidase, and urease. The second group are redox enzymes that catalyze oxidation or reduction reactions. These include glucose oxidase, xanthine oxidase, catalase, peroxidase, lipoxidase, and cytochrome reductase. In the third group are transferase enzymes that transfer groups from one molecule to another. Examples of these are glutamicpyruvic transaminase, glutamicoxalacetic transaminase, transmethylase, phosphopyruvic transphosphorylase.
In the usual practice of the present invention, one selects a first or model enzyme. One then selects a second native or so-called host protein to be modeled after the model enzyme to produce an enzyme-like modified protein. As discussed above, in many cases the native protein is itself enzymatically active, with respect to a given substrate, since many common enzymes are available in large quantities at fairly low costs in homogeneous sample form. However, nonenzymatic proteins are equally useful when they can be either purchased in pure form or purified by conventional means for use with the present process. One example of such a nonenzymatic protein which may be used as a native protein for the starting material of the bovine serum albumin (BSA). BSA is available in relatively pure form at fairly low cost from numerous commercial sources.
By practicing the process of the present invention, one can custom-tailer the native protein to a different stable enzyme-like modified protein form which shows the catalytic activity characteristics of the enzyme which has been modeled. The ability to custom-tailor a native protein into a predetermined catalytic activity provides greater advantages in a wide range of chemical and industrial situations. For example, if one wishes to use an enzyme which is in short supply, is very expensive or very difficult to isolate and/or purify, such an enzyme may serve as a model enzyme for the preparation of an enzymelike modified protein analogue by the present process to mimic its activity.
Thus, a native protein which is available in large quantities or at low cost can be reformed or modified by the process of the present invention to convert the available native protein starting material into an enzyme-like modified protein form of a less available and/or more expensive enzyme.
In the preferred embodiment of the invention, a native protein starting material is purified and dissolved in a near neutral aqueous solvent in the presence of a suitable buffer to maintain the solution near neutrality. Subsequently, the native protein is grossly denatured by any of the expedients described hereinabove to produce a grossly denatured, preferably, soluble form of the native protein starting material. Next, the grossly denatured protein is partially renatured or refolded to produce a partially denatured protein.
Subsequently, an inhibitor for the model enzyme is admixed with the partially denatured protein.
Sufficient time and sufficient temperature are provided for a partially denatured protein-inhibitor complex to form. Subsequently, to preserve the new, enzyme-like modified protein, the partially denatured native protein portion of the proteininhibitor complex must be stabilized.
The new protein is stabilized by cross-linking of the protein to produce the enzyme-like modified protein. Often, cross-linking is done as disclosed above by glutaraldehyde cross-linking agent since it is inexpensive. However, any of the abovedescribed cross-linking agents can be utilized effectively in the conventional manner.
The process of the present invention produces a new, enzyme-like modified protein which exhibits a number of advantages and uses. By the discoveries of the present invention an enzymelike modified protein can be produced which is stable and exhibits a new enzyme-like catalytic activity which was not present in the native protein. Such modified proteins showing enzymelike catalytic behaviour are useful to perform catalytic anabolic and catabolic reactions instead of a naturally occurring enzyme.
In all embodiments of the present invention the inhibitor of the model enzyme is removed after synthesis of the enzyme-like modified protein.
Typically repeated washings of the immobilized modified protein is sufficient to remove the inhibitor. Buffered aqueous solution can also be used to remove the inhibitor, such buffers are exemplified hereinafter.
For convenience of disclosure, all patent documents and publications mentioned herein above are incorporated by reference.
Other embodiments of the present invention will be apparent to those of ordinary skill in the art from a consideration of this specification or practice of invention disclosed herein. It is intended that the Examples in the specification be considered as examplary only with the scope and spirit of the invention being indicated by the claims. The following Examples ar exemplary of the various embodiments of the process of the present invention discussed hereinabove.
Example 1
Sixty mg of chromatographically purified parcreatic ribonuclease (RNase) native enzyme, purchased from Sigma Chemical Company, lot 1 1 OF02051, type ilA, No. R-5000, is dissolved in 3 ml of 8 M urea denaturing agent containing 0.1
M 2-amino-2-(hydroxymethyl)-1 ,3-propanediol- HCI buffer (hereinafter tris buffer), at pH 8 with slow stirring at 250C.
Next, 0.1 ml of neat beta-mercaptoethanol denaturing agent is added in the solution to break disulphide bonds. The resulting solution is shaken slowly for 1 5 minutes at 250C. The solution is then placed in a stoppered Erlenmeyer flask under a nitrogen atmosphere for 1 6 hours at 250C. The closed environment of the flask is maintained by a pressurized nitrogen tank releasing nitrogen gas into the flask with the flask vented into a water trap.
Next, 3 ml of the solution is chromatographed across a gel filtration column which is 12 in. x 1 in., containing Sephadex brand G-1 5 gel filtration material. Sephadex is cross-linked, beaded, high molecular weight polysaccharide which has been cross-linked with epichlorohydrin, marketed by
Pharmacia Fine Chemicals. Acetic acid at 0.1 M pH 3, is used as the eluant for the gel column. The eluant flow rate is maintained at 1 ml/min via a slow speed peristaltic pump. As absorbence monitor is placed at the outflow point of the chromatography column and an ultraviolet detector set at 276 nm is used to detect eluting protein fractions. A major protein fraction of about 5 ml elutes from the column under these conditions and is collected in a small beaker.The protein fraction is analyzed using an ACTA Ill spectophotometer from Beckman Instruments
Company. The molarity of the protein fraction is determined to be 2.67 x 10-5 wherein the 280 angstrom absorbence coefficient is 0.254, the molecular weight of the protein is 13000 daltons and the extinction coefficient value, E, is 7.3 for a 1% solution.
To the 5 ml of the protein containing eluant collected above is added 1 ml of 1.0 M tris-HCI buffer, pH 8; 1 ml of 1 m M eth mM ethylenediaminetetra- acetic acid (EDTA); 1 ml of 5x10 M reduced glutathione; 1 ml of 5x10-4 M of oxidized glutathione and 1 ml of 0.02 M tryptamine-HCI inhibitor. The tryptamine-HCI is added as the inhibitor, while the other reagents (namely, the
EDTA and glutathione) are added in accordance with the teaching of Lloyd Chavez, Jr. and Harold
Scheraga in "Folding or Ribonuclease, S-Protein and Des (121-124) ribonuclease during
Glutathione Oxidation of Reduced Proteins", 1980, Biochemistry, 19, 996-1004. The resultant solutions shows a pH of 5.5. The solution is stirred for 1.5 hours at the 5.5 pH under slow stirring.Subsequently, the pH is raised to about 8.0 by the addition of 100 mg of tris base crystals. The resulting tris containing solution is stirred slowly at pH 8, at 250 C, for an additional 2.5 hours. A fluffy white preciptate is formed during the stirring process. At the end of the 2.5 hour period, the solution is dialyzed against 1 mM tris-HCI buffer, pH 7.2, containing 0.005 M tryptamine inhibitor. The dialysis membrane is a Spectrapor brand membrane tubing, No. 2 size, having a molecular weight exclusion range of 12-14,000 daltons. The dialysis procedure included two buffer changes with a gross volume of 7000 ml of buffer over a 1 7 hour period, at 0.5 0C, with slow shaking of the dialysis tubing in the dialysis media.
After dialysis, 2 ml of the enzyme-like modified protein containing solution is chromatographed across a Sephadex brand G-1 5 column, the column dimension being 1/2 inchx 12 inches, the column being filled with gel filtration agent using 1 mM tris-HCI buffer at pH 7 as the eluant. Such a gel filtration column is used to separate low molecular weight materials from protein materials. The eluant flow rate is 1 ml/min. The eluant was moinitored at 254 nm to detect eluting enzyme-like modified protein. A first portion of eluting enzyme-like modified protein is collected and assayed vs. substrate for esterase enzyme. The substrate used is typtophan methyl ester (TME), the substrate being purchased from
Sigma Chemical Company, lot 1 09C-0048, No.
T-5505.
The activity of the esterase enzyme-like modified protein is tested as follows. The protein fraction collected above is assayed by high pressure liquid chromatography (HPLC) to determine activity toward the TME substrate. The assay conditions are as follows. The HPLC column eluant is 0.03 M acetate, pH 6. The column support material is porous silica bonded phase material containing carboxyl side chains. The column is stainless steel composition and is 2 mmx25 cm, with a flow rate of 4 ml/min.
maintained by conventional high pressure pump, for example an Altex, Model 110 A pump. The column eluant is detected by a conventional ultraviolet monitor at 254 nm.
The assay sample is prepared as follows. One ml of the esterase enzyme-like modified protein (with an absorption of 0.222, at 280 nm, equating 0.335 mg/ml) is admixed with 8 ml of 5 mM tris
HCI buffer, pH 8 and 1 ml of 0.1 M TME substrate.
The assay control solution is prepared by adding 8 ml of 5 mM tris-HCI buffer, pH 8, to 1 ml of 0.1 M
TME and 1 ml of the tris buffer, pH 7, used as the eluant solution. The pH of both the control and assay sample solution is 6.6.
One ml of the sample is removed from the beaker, using a 2 ml hypodermic syringe, with an 18 gauge needle. The one ml of sample is passed through a 20 microliter injection sample loop onto the HPLC column. The injection time is recorded.
This procedure is repeated using the control solution Both sample and control are chromatographed 4 times in order to obtain a plot of molarity of tryptophan versus time for sample and control to elute from the column.
A statistical analysis is performed with the data obtained from the above procedure which shows a slope of 0.3171 x10-5 M/min., with an error of 0.00685x 10-5 M/min. is determined for the sample. A slope of 0.2878 x 10-5 M/min. with an error of 0.0091 x10-5 M/min. is determined for the control.
The following expression is used to calculate the activity of the esterase enzyme-like modified protein according to the present invention.
(change in slope+error) Vs (1 06) Activity=
MP wherein: change in slope is the difference between the sample and control slopes (in this example 0.0293); error is the sum of the errors in the sample and control slopes (in this example 0.016); Vs is the sample volume in liters; 106 iS micromoles/mole; and MP is mg of modified protein in the assay.
In the above calculation, the concentration of the modified protein is calculated from its absorbance at 280 nm, using the extinction coefficient for ribonuclease, which is 7.3 for a 1% solution. The extinction coefficient is disclosed in the reference entitled Int. J. Pep tide Protein Res. 5, 49-62 (1973) authored by D. M. Kirschenbaum.
The assay results are as follows:
Substrate
TME {Units/g) Initial activity 0.000
Final activity 8.0+0.717
The results show that the esterase enzyme-like
modified protein prepared according to the
present invention exhibits activity with respect to
the esterase enzyme substrate TME where no
activity is previously detected in native
ribonuclease enzyme. This illustrates the
conversion of one genus of enzyme, namely, a
nuclease to a second genus of protein, namely, an
esterase enzyme-like modified protein.
The results show that the esterase enzyme-like
modified protein prepared according to the
present invention exhibits activity with respect to
the esterase enzyme substrate TME where no
activity is previously detected in native
ribonuclease enzyme. This illustrates the
conversion of one genus of enzyme, namely, a
nuclease, to a second genus of protein, namely,
an esterase enzyme-like modified protein.
Example 2
One hundred and twenty mg of
chromatographically purified bovine pancreatic
ribonuclease (RNase) native enzyme, purchased
from Sigma Chemical Company, lot 110F-02051
Type, llA, No. R-5000, is dissolved in 6 ml of 8 M
urea containing 0.1 M tris-HCI buffer, pH 8 with
slow stirring at 250C. Next, 0.2 ml of beta
mercaptoethanol denaturing agent is added and
the solution is stirred slowly for 1 5 minutes at
250C. The solution is then allowed to stand under
a nitrogen atmosphere for 16 hours at 250C in a
stoppered flask. The closed environment is
maintained by a pressurized nitrogen tank constantly delivering nitrogen into the flask with the flask vented in to a water trap.
Next, 5 ml of the solution is chromatographed on a Sephadex brand G-1 5 gel material column which is a 12 inchx 1 inch column filled with gel.
The column eluant is 0.1 M acetic acid at pH 3.
The flow rate of the eluant through the column is 1 ml/min. The absorbence of the outflow of the column is monitored at 276 nm by an ultraviolet detector. A gross protein fraction of 5 ml is collected. The fraction is analyzed on a Beckman
Instruments Company ACTA Ill spectrophotometer. The molarity of the collected protein fraction is determined as 6.64x 10-5 wherein the 280 absorbence is 0.63, the molecular weight of the protein is 1 3000 daltons and the extinction coefficient value, E, is equal to 7.3 for a 1% solution.
To the 5 ml of protein material collected above is added 0.5 ml of 1.0 M tris-HCI buffer, pH 8; 0.5 ml of 1 mM EDTA;0.5 ml of 5x10-4 M reduced glutathione; 0.5 ml of 5x10-4 M oxidized glutathione and 0.5 ml of 0.02 M tryptamine inhibitor for esterase enzyme. The tryptamine is added as an inhibitor while the EDTA and glutathione are added in accordance with the teaching of Lloyd Chavez, Jr. and Harold Scheraga in "Folding of Ribonuclease, S-Protein and Des (121-124) ribonuclease during Glutathione
Oxidation of Reduced Proteins", 1980,
Biochemistry, 19, 996-1004.
At the end of the 4.0 hour period, resultant solution shows a pH of 5.0. After stirring the resultant solution for 0.5 hours, at the pH 5 value, the pH is raised to 8 with the addition of 100 mg of tris based crystals. The solution is stirred slowly at pH 8 and 250C for 4 hours. During the stirring process a fluffy white precipitate forms.
At the end of the 4 hour period, resulting
solution is dialyzed against 1 mM tris HCI buffer,
at pH 7, containing 2% tryptamine inhibitor. A spectropor brand membrane dialysis tubing, No. 2
size, with a molecular weight cutoff range of 12
14,000 daltons is used for the dialysis. The
dialysis is conducted with two buffer changes for
a gross buffer volume of 7000 mi over a 17 hour
period, at 0--5oC. with slow shaking at 0--5 OC.
Two ml of the protein solution above is
chromatographed across a Sephadex brand G-15 gel column which is 1/2 inchxl2 inches using as
an eluant 1 mM tris-HCI buffer, at pH 7. The
eluant flow of rate is 1 ml/min. The absorbence of
the eluting solution is monitored: at 254 nm. The
first half of the eluting protein fraction is collected
and assayed against esterase substrate, namely,
tryptophan methyl ester (TME) purchased from
Sigma Chemical Company, lot 1 09C-0048, No.
T-5505.
The assay for enzymatic activity of the newly
synthesized esterase enzyme-like modified
protein prepared according to the present
invention is performed on a HPLC system. The
column is packed with a support material which is a porous silica bonded phase material having
carboxyl side chains. The column eluant is 0.03 M
acetate at pH 6. The column is of stainless steel
composition and 2 mmx25 cm in size. Aflow rate
of 4 ml/min is maintained by a conventional high
pressure pump, for example an Altex, Model
1 10A pump. The column eluant is detected by a
conventional ultraviolet monitor at 254 nm and
the tryptophan peak heights are recorded.
The assay sample is prepared as follows. Three ml of the esterase enzyme-like modified protein (with a 280 absorbence of 0.450 at 280 nm, equaling 0.67 mg/ml) is admixed with 6 ml of 1 mM tris-HCI buffer, pH 7.5 and 1 ml of 0.1 M TME substrate. An assay control solution is prepared by adding 6 ml of 1 mM tris-HCI buffer, pH 7.5, to
1 ml of TME substrate and 3 ml of the Sephadex brand G-1 5 eluant buffer, namely, the 1 mM tris buffer, at pH 7. The pH ot both the control and the assay sample is 6.4.
One ml of the sample is removed from the beaker, using a 2 ml. hypodermic syringe, with an 18 gauge needle. The one ml of sample is passed through a 20 microliter injection sample loop onto the HPLC column. The injection time is recorded.
This procedure is repeated using the control solution. Both sample and control are chromatographed 4 times in order to obtain a plot of molarity of tryptophan versus time for sample and control to elute from the column.
A statistical analysis is performed with the data obtained from the above procedure which shows a slope of 0.81333x 10-5 M/min., with an error of 0.1021 x 10-5 is determined for the sample. A slope of 0.54062x10-5 M/min. with an error of 0.03291 x 10-5 M/min. is determined for the control.
The following expression is used to calculate the activity of the esterase enzyme-like modified protein according to the present invention.
(change in slope+error) Vs (106)
Activity=
MP wherein: change in slope is the difference between the sample and control slopes (in this example 0.272713); error is the sum of the errors in the sample and control slopes (in this example 0.134); VS is the sample volume in liters; 106 is micromoles/mole; and MP is mg of modified protein in the assay.
In the above calculation, the concentration of the modified protein is calculated from its absorbance at 280 nm, using the extinction coefficient for ribonulcease, which is 7.3 for a 1% solution. The extinction coefficient is disclosed in
the reference entitled Int J. Peptide Protein Res.
5,4962 (1973) authored by D. M.
Kirschenbaum.
The assay results are as follows:
Substrate
TME (Units/g) Initial activity 0.000
Final activity 13.62+6.62
The results show that the esterase enzyme-like modified protein prepared according to the present invention exhibits activity with respect to the esterase enzyme substrate TME where no activity is previously detected in native ribonuclease enzyme, namely, a nuclease to a second genus of protein, namely, an esterase enzyme-like modified protein.
Example 3
One hundred mg of bovine serum albumin (BSA), purchased from Sigma Chemical Company, lot 90F-93 15' No. A-7 511, is dissolved in 5 ml of 8 M urea containing 0.1 M tris buffer pH 8, with slow stirring at 250C.
Next, 0.2 ml of beta-mercaptoethanol denaturing agent is added to the solution. The solution is shaken slowly for 1 5 minutes at 250C.
The solution is next placed under a nitrogen atmosphere for 16 hours at 250C as disclosed in
Example I.
Next, 5 ml of the solution is chromatographed across a gel filtration column, containing
Sephadex brand G-1 5 gel filtration material. The column is 12 inchesx 1 inch and is filled with
Sephadex brand G-1 5 gel. Acetic acid at 0.1 M, pH 3, is used as the eluant for the gel column. The eluant flow rate is maintained at 1 ml/min via a slow speed peristaltic pump of conventional design. An absorbence monitor is placed at the outflow point of the chromatography column and an ultraviolet detector set at 276 nm is used to detect eluting protein fractions. At the point which protein starts eluting from the column collection is begun and a gross of 5 ml of protein is collected.
To the 5 ml of collected protein is added 1 ml of 1.0 M tris-HCI buffer, pH 8; 1 ml of 1 mM EDTA; 1 ml of 5x10M M reduced glutathione; 1 ml of 5x10-4 M oxidized glutathione and 1 ml of 0.02 M tryptamine esterase inhibitor. The resultant solution shows a pH of 5.2. The resulting solution is stirred slowly for 0.5 hours at pH 5.2. After 0.5 hours, the pH of the solution is raised to 6 with the dropwise addition of 0.1 M
NaOH. The solution at pH 6 is allowed to stir slowly at 250C for an additional 4 hours. During the stirring process, a fluffy white precipitate is f6rmed. At the end of the 4 hour period the solution is dialyzed against 1 mM tris-HCI buffer, pH 7, containing 2% tryptamine inhibitor. The tryptophan is added as the inhibitor while other reagents are added as taught by Chavez et al discussed above. The dialysis is performed using a dialysis membrane tubing, namely, Spectrapor brand dialysis tubing, No 2 size, having a molecular weight exclusion range of 12-14,000 daltons. The dialysis procedure includes 2 buffer changes with a gross buffer volume of 7000 ml of buffer over a 17 hour period, at 0.50C, with slow shaking of the dialysis tubing in the dialysis media.
After dialysis, 4 ml of the esterase enzyme-like modified protein containing solution is chromatographed across a Sephadex brand G-10 column, the column dimension being 1/2 inchx 12 inches and filled with gel agent using 1 mM tris-HCI buffer at pH 7 as the eluant. The eluant outflowing from flow rate is 1 ml/min. The eluant of the column is monitored at 254 nm to detect eluting enzyme-like modified protein. A first portion of eluting enzyme-like modified protein is collected and assayed against substrate for esterase enzyme. The substrate used is tryptophan methyl ester (TME), the substrate being purchased from Sigma Chemical Company, lot 1 09C-0048, No. T5505.
The activity of the esterase enzyme-like modified protein is tested as follows. The protein fraction collected above is assayed by HPLC to determine activity toward the TME esterase substrate. The assay conditions are as follows.
The HPLC column eluant is 0.03 M acetate, pH 6.
The column support material is a porous silica bonded phase material containing carboxyl side chains. The column is stainless steel composition and is 2 mmx25 cm, with an eluant flow rate of 4 ml/min. maintained by a conventional high pressure pump, for example an Altex, Model 11 OA pump. The column eluant is detected by a conventional ultraviolet monitor at 254 nm and at 0.05 A.
The assay sample is prepared as follows. Five ml of 0.03 M acetate buffer, pH 6, is mixed with 1 ml of 0.1 mM TME and with 4 ml of the esterase enzyme-like modified protein prepared above (with an adsorption at 280 nm of 0.016 equaling 0.024 mg/ml). The assay control is prepared by adding 5 ml of 0.03 M acetate pH 6 to 1 ml of 0.1
M TME and to 4 ml of the eluant, namely, the tris
HCI buffer, pH7. Both the control solution and the assay sample solution show pH 5.8.
One ml of the sample is removed from the beaker, using a 2 ml hypodermic syringe, with an 18 gauge needle. The one ml of sample is passed through a 20 microliter injection sample loop onto the HPLC column. The injection time is recorded.
This procedure is repeated using the control solution. Both sample and control are chromatographed 4 times in order to obtain a plot of molarity of tryptophan versus time for sample and control to elute from the column.
A statistical analysis is performed with the data obtained from the above procedure which shows a slope of 0.05596x 10-5 M/min., with an error of 0.0021 3x 10-5 M/min. is determined for the sample. A slope of 0.6244857 x 10-5 M/min. with an error of 0.000823 xl 0-5 M/min. is determined for the control.
The following expression is used to calculate the activity of the esterase enzyme-like modified protein according to the present invention.
(change in slope+error) Vs (10e) Activity MP wherein: Change in slope is the difference between the sample and control slopes (in this example 0.0314); error is the sum of the errors in the sample and control slopes (in this example 0.00296); Vs is the sample volume in liters; 106 is micromoles/mole; and MP is mg of modified protein in the assay.
In the above calculation, the concentration of the modified protein is calculated from its absorbance of 280 nm, using the extinction coefficient for ribonuclease, which is 6.62 for a 1% solution. The extinction coefficient is disclosed in the reference entitled Int. J. Peptide
Protein Res. 5,49-62(1973) authored by D. M.
Kirschenbaum.
The assay results are as follows:
Substrate
TME lUnitslgJ Initial Activity 0.00
Final Activity 32.7+3.08
The results show that the esterase enzyme-like modified protein prepared according to the present invention exhibits activity with respect to the esterase enzyme substrate TME.
No esterase activity is previously detected in the native BSA protein.
This illustrated the conversion of one genus of nonenzymatic protein, an albumin, to another genus of protein, an enzymatically active esterase enzyme-like modified protein.
Example 4
Two hundred fifty mg of BSA, purchased from
Sigma Chemical Company, lot 90F-8351, No.
7511, is dissolved in 25 ml of 8 M urea with slow stirring, at pH 7.8 for 2 hours at 250C. After the 2 hour stirring period, 1 ml of 10 mM betamercaptoethanol reducing agent solution is added. The resulting solution is stirred slowly for 1 hour, at pH 7.6, at 25 C.
Next, 75 ml of a 1% solution of tryptamine esterase enzyme inhibitor is added. The solution is slowly stirred for 2 hours, at pH 7.0.
Next, the protein is cross-linked as follows. The solution containing the protein is placed in a dialysis bag which is Spectrapor brand dialysis tubing, No. 2 type. The protein contained in the dialysis bag is dialyzed against 1% tryptamine inhibitor solution in 1 mM tris buffer at pH 7.0, at 0--5"C for 17 hours.
The resultant esterase enzyme-like modified portion is purified as follows. Two ml of the preparation above is chromatographed across a
Sephadex G-10 chromatography column using 0.03 M acetate buffer pH 6, as the eluant. The eluant flow rate is 2 ml/min. The initial half of the protein peak is approximately 5 ml of eluant volume and exhibits an absorbence of 0.666 at 280 nm.
The activity of the esterase enzyme-like modified protein prepared above is tested as follows. The protein fraction collected above is assayed by HPLC. The column support material is porous silica bonded phase material containing carboxyl side chains. The column is stainless steel composition and is 2 mmx25 cm. The eluant flow rate is 4 ml/min. using 0.03 M acetate, pH 6.
The column eluant protein fraction is detected by a conventional ultraviolet monitor at 254 nm.
The assay sample is prepared as follows. Five ml of 0.03 M acetate, pH 6, is admixed with 1 ml of 0.1 M TME and 4 ml of the protein containing solution above. The assay control solution is prepared by admixing 9 ml of 0.03 M acetate, pH 6, with 1 ml of 0.1 M TME substrate. The pH of both the control and assay sample solution is 6.0.
One ml of the sample is removed from the beaker, using a 2 ml hypodermic syringe, with an 18 gauge needle. The 1 ml of sample is injected through a 20 microliter injection sample loop onto the HPLC column. The injection time is recorded.
This procedure is repeated using control solution.
Both sample and control are chromatographed 4 times in order to obtain a plot of molarity of tryptophan versus time for sample and control to elute from the column.
A statistical analysis is performed with the data obtained from the above procedure which shows a slope of 0.0516 xl 0-6 M/min., with an error of 0.004 M/min for the sample. A slope of 0.0287x 10-5 M/min with an error of 0.0016x 10-5 M/min for the control.
The following expression is used to calculate the activity of the esterase enzyme-like modified protein according to the present invention.
(change in slope+error) Vs (106)
Activity
MP wherein: change in slope is the difference between the sample and control slopes;
error is the sum of the errors in the sample and the control slope
Vs is the sample volume in liters;
10+6 is micromoles/mole; and
MP is mg of modified protein in the assay.
In the above calculation, the concentration of the modified protein is calculated from its absorbance at 280 nm, using the extinction coefficient for bovine serum albumen, which is 6.6280 for a 1% solution. The above procedure is disclosed in the reference entitled Int J. Peptide
Protein Res. 5,49-62 (1973) authored by D. M.
Kirschenbaum.
The assay results are as follows.
Substrate
TME (Units/g) Initial Activity 0.0
Final Activity 0.57+.1 6 The results show that the modified esterase enzyme-like protein prepared according to the present invention exhibits activity with respect to esterase enzyme substrate TME. No activity with
respect to esterase substrate TME is previously detected in the native BSA.
This illustrates the conversion of one genus of non-enzymatic protein, an albumin to another genus or protein, namely, an enzymatically active esterase enzyme-like modified protein.
Example 5
To demonstrate that native bovine serum albumin (BSA) protein shows no catalytic activity with respect to the L-trypophan methyl ester (TME) substrate of Example 4 above, the following control procedure is performed.
One g of BSA, from Sigma Chemical Company,
Type 7511, lot 90F-9315, is dissolved in 25 ml of distilled deionized water, with slow stirring at 250C. To this solution is added 75 ml of a 1% tryptamine-HCI solution. The resulting solution is incubated for 1 5 minutes at 250C. This solution is next dialyzed in a No. 2 sized Spectra/PorR dialysis tube against 3500 ml of a 1% tryptamine
HCI solution for four hours. The No. 2 tubing has a molecular weight exclusion range of 12-14,000 daltons. The temperature of the solution is maintained at 50C. OC. and the pH at 6.0 during the dialysis procedure. After the four hour dialysis procedure, two ml of the solution is chromatographed across a Sephadex brand G-10 gel chromatography column.The column is eluted with 0.03 M acetate buffer, pH 6, at a flow rate of 2 ml/min. The column size is 25 inchx 1/2 inch.
Two distinct peaks are collected. The first peak is eluted about 30 ml. The first peak is identified by a 300-200 nm scan on an ACTA 3
Spectrophotometer (Beckman Instruments
Company) as being BSA protein. The second peak is eluted at 60 ml and is identified by ultraviolet spectrophotometry as tryptamine.
Four ml of the collected BSA is next assayed versus TME substrate for possible enzymatic activity. The assay is conducted as follows. A high pressure liquid chromatography system is used for the assay. The column is a 2 mmx 25 cm, stainless steel column packed with porous silica particles containing carboxyl size chains, with an average particle pore size of 40 microns, purchased from Baker Chemical Company.
The column eluant is 0.03 M acetate, pH 6, at a flow rate of 4 ml/min. The absorbance of the outflow of the column is monitored at 254 nm.
Five ml of the 0.03 M acetate, pH 6 and 1 ml of 0.1 M TME substrate are mixed with 4 ml of the
BSA solution above.
The assay control is prepared by mixing 9 ml of 0.03 M acetate, pH 6 and 1 ml of 0.1 M TME substrate. The pH of both the control and sample is 6.0.
One ml of the assay sample is removed from a sample beaker with a 2 ml hypodermic syringe with an 18 gauge needle and injected through a 20 microliter injection sample loop onto the column. The time of injection is recorded.
The procedure is then repeated using the assay control solution. Both the sample solution and control solution are chromatographed four times in order to obtain a plot of molarity of TME versus time for the assay sample and the assay control solutions.
A statistical analysis of the data obtained shows a slope of 0.19689x10-5 M/min, with an error of 0.0089 x 10-5 M/min for the BSA assay sample. For the assay control sample, a slope of 0.20296x 10-5 M/min, with an error of 0.0062 x10-5 M/min is determined. The slopes, plus the sums of the errors, are virtually identical.
Accordingly, the native BSA protein shows no measurable catalytic activity properties with respect to TME substrates.
Example 6
To demonstrate that native ribonuclease enzyme shows no catalytic activity with respect to L-tryptophan methyl ester (TME) substrate of
Examples 1-2 above, the following control is performed.
Sixty mg of ribonuclease enzyme, from Sigma
Chemical Company, Type R-5000, lot 20F-2010, is dissolved in 100 ml of 1 mM tris buffer, at pH 7, with slow stirring at 250C.
The ribonuclease containing solution is then dialyzed using a No. 3 Spectra/PorR dialysis tube against 3500 ml of 1 mM tris buffer, pH 7, for 17 hours at 05. 0. The No. 3 tubing has a molecular weight exclusion range of 35-4500 daltons.
Next, 1 ml of the ribonuclease containing solution is assayed versus TME substrate for possible enzymatic activity with respect to TME. The assay is conducted as follows.
A high pressure liquid chromatography system is used for the assay. The column is a 2 mmx25 cm stainless steel column packed with porous silica containing carboxyl side chains having an average pore size of 40 microns, purchased from
Baker Chemical Company. The column eluant is 0.03 M acetate, pH 6, at a flow rate of 7 ml/min.
The absorbance of the column outflow is monitored at 280 nm.
The assay sample solution containing native ribonuclease is prepared as follows. Eight ml of one mM tris buffer, pH 8.05, is admixed with one mlofOl MTME,pH3.4and1 mlofthe ribonuclease solution prepared above. The assay control solution is prepared by admixing 8 ml of 1 mM tris buffer, pH 8.05; one ml of 0.1 M TME, pH 3.4 and one ml of one mM tris buffer, pH 7.0. The pH of the control and assay solutions is 6.5.
Next, one ml of the assay sample solution is removed from the sample beaker using a 2 ml hypodermic syringe with an 18 gauge needle and injected onto the column through a 20 microliter injection sample loop. The time of injection is recorded.
This procedure is then repeated using the assay control solution. Both sample and control solutions are chromatographed four times in order to obtain a plot of molarity of TME versus time for sample and control solutions.
A statistical analysis of the data obtained shows virtually identical slopes of 0.1400+0.003 for both control and sample solutions.
Accordingly, the native ribonulcease shows no measurable catalytic activity properties with respect to the TME substrate.
Example 7
To demonstrate that native bovine serum albumin (BSA) activity with respect to Ltryptophan methyl ester (TME) substrate of
Example 3 above, the following control is performed.
One hundred mg of BSA from Sigma Chemical
Company, No.7511, lot 90F-8351, is dissolved in 100 ml of one mM tris buffer at pH 7, with slow stirring at 250C.
The BSA containing solution is then dialyzed using a No. 2 Spectra/PorR dialysis tube against 3500 ml of 1 mM tris buffer, pH 7, for 17 hours at 0-50C. The No. 2 tubing has a molecular weight exclusion range of 1 2-14,000 daltons. Next, one ml of the BSA containing solution is assayed versus TME substrate for possible enzymatic activity with respect to TME. The assay is conducted as follows.
A high pressure liquid chromatography system is used for the assay. The column is a 2 mmx25 cm stainless steel column packed with porous silica containing carboxyl side chains having an average pore size of 40 microns, purchased from
Baker Chemical Company. The column eluant is 0.03 M acetate, pH 6, at a flow rate of 7 ml/min.
The absorbance of the column outflow is monitored at 280 nm.
The assay sample solution containing native
BSA is prepared as follows. Eight ml of one mM tris buffer, pH 7.5 is admixed with one ml of 0.1
M TME, pH 3.2 and one ml of the ribonuclease solution prepared above, the assay control solution is prepared by admixing 8 ml of one mM tris buffer, pH 7.5, one ml of 0.1 M TME, pH 3.2 and one ml of one mM tris buffer, pH 7.0. The pH of the control and assay solutions is 5.8.
Next, one ml of the assay sample solution is removed from the sample beaker using a 2 ml hypodermic syringe with an 1 8 gauge needle and injected onto the column through a 20 microliter injection sample loop. The time of injection is recorded.
This procedure is then repeated using the assay control solution. Both sample and control solutions are chromatographed four times in order to obtain a plot of molarity of TME versus time for sample and control solutions.
A statistical analysis of the data obtained shows virtually identical slopes of 0.06+.0065 for both control and sample solutions. Accordingly, the native ribonuclease shows no measurable catalytic activity properties with respect to the
TME substrate.
Claims (29)
1. A process for chemically altering the substrate specificity of a native protein to produce an enzyme-like modified protein, comprising:
a. selecting an enzyme to be modeled;
b. grossly denaturing a native protein;
c. partially renaturing said grossly denatured
native protein to produce a partially
denatured protein;
d. contacting said partially denatured protein
with an inhibitor for said model enzyme to
form a partially denatured protein-model
enyzme inhibitor complex; and
e. cross-linking said partially denatured protein
in said protein-inhibitor complex.
2. The process of claim 1 wherein said native protein is grossly denatured by forming an aqueous solution of said native protein and maintaining said aqueous solution at a temperature and for a time sufficient to grossly denature said native protein.
3. The process of claim 2 wherein said temperature is between 50 and 70 degrees centrigrade.
4. The process of claim 1 wherein said native protein is grossly denatured by admixing said native protein with water to form an aqueous solution and admixing the resulting aqueous solution with a denaturing agent.
5. The process of claim 4 wherein said denaturing agent is an organic acid.
6. The process of claim 5 wherein said organic acid is selected from the group consisting of acetic acid, formic acid, propionic acid and citric acid.
7. The process of claim 4 wherein said denaturing agent is an inorganic acid.
8. The process of claim 7 wherein said inorganic acid is selected from the group consisting of nitric acid, phosphoric acid, sulfuric acid and hydrochloric acid.
9. The process of claim 4 wherein said denaturing agent is guanidine hydrochloride.
10. The process of claim 4 wherein said denaturing agent is urea.
11. The process of claim 4 wherein said denaturing agent is a mixture of urea and betamercaptoethanol.
12. The process of claim 1 wherein said partially denatured protein is cross-linked by contacting said protein with a cross-linking agent.
1 3. The process of claim 1 2 wherein said cross-linking agent is glutaraldehyde.
14. A process for chemically altering the substrate specificity of a native protein to produce an enzyme-like modified protein, comprising:
a. selecting an enzyme to be modeled;
b. grossly denaturing a native protein;
c. admixing said grossly denatured protein with
an inhibitor of said model enzyme;
d. partially renaturing said grossly denatured
protein, in the presence of said inhibitor, to
produce a partially denatured protein
inhibitor-complex; and
e. cross-linking said partially denatured protein
portion of said protein-inhibitor complex.
1 5. The process of claim 1 4 wherein said native protein is grossly denatured by forming an aqueous solution of said native protein and maintaining said aqueous solution at a temperature and for a time sufficient to grossly denature said native protein.
16. The process of claim 1 5 wherein said temperature is between 50 and 70cC.
1 7. The process of claim 14 wherein said native protein is grossly denatured by admixing said native protein with water to form an aqueous solution and admixing the resulting aqueous solution with a denaturing agent.
1 8. The process of claim 17 wherein said denaturing agent is an organic acid.
1 9. The process of claim 1 8 wherein said organic acid is selected from the group consisting of acetic acid, formic acid, propionic acid and citric acid.
20. The process of claim 1 7 wherein said denaturing agent is an inorganic acid.
21. The process of claim 20 wherein said inorganic acid is selected from the group consisting of nitric acid, phosphoric acid, sulfuric acid and hydrochloric acid.
22. The process of claim 1 7 wherein said denaturing agent is guanidine hydrochloride.
23. The process of claim 1 7 wherein said denaturing agent is urea.
24. The process of claim 1 7 wherein said denaturing agent is a mixture of urea and betamercaptoethanol.
25. The process of claim 14 wherein said partially denatured protein is cross-linked by contacting said protein with a cross-linking agent.
26. The process of claim 25 wherein said cross-linking agent is glutaraldehyde.
27. The enzyme-like modified protein product of the process of claim 1.
28. The enzyme-like modified protein product of the process of claim 1 4.
29. A process as claimed in claim 1 or claim 14, substantially as described.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41834482A | 1982-09-15 | 1982-09-15 |
Publications (3)
Publication Number | Publication Date |
---|---|
GB8314851D0 GB8314851D0 (en) | 1983-07-06 |
GB2127024A true GB2127024A (en) | 1984-04-04 |
GB2127024B GB2127024B (en) | 1986-04-23 |
Family
ID=23657724
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB08314851A Expired GB2127024B (en) | 1982-09-15 | 1983-05-27 | Modified proteins and process for the production thereof |
Country Status (8)
Country | Link |
---|---|
JP (1) | JPS5959188A (en) |
AU (1) | AU538170B2 (en) |
BR (1) | BR8304970A (en) |
CA (1) | CA1201990A (en) |
DE (1) | DE3329624A1 (en) |
FR (1) | FR2532949B1 (en) |
GB (1) | GB2127024B (en) |
IT (1) | IT1173739B (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4766205A (en) * | 1985-11-13 | 1988-08-23 | Beatrice Companies, Inc. | Method for isolation of recombinant polypeptides in biologically active forms |
DE3611817A1 (en) * | 1986-04-08 | 1987-10-15 | Boehringer Mannheim Gmbh | METHOD FOR RENATURING PROTEINS |
US5179199A (en) * | 1986-10-20 | 1993-01-12 | Genzyme Corporation | Protein purification |
US4912200A (en) * | 1987-05-11 | 1990-03-27 | Schering Corporation | Extraction of granulocyte macrophage colony stimulating factor from bacteria |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2088880A (en) * | 1980-12-04 | 1982-06-16 | Owens Illinois Inc | Process for preparing semisynthetic proteins |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3666627A (en) * | 1968-10-14 | 1972-05-30 | Corning Glass Works | Method of stabilizing enzymes |
JPS5325030B2 (en) * | 1972-12-19 | 1978-07-24 | ||
US3930950A (en) * | 1974-04-09 | 1976-01-06 | The Ohio State University Research Foundation | Method of immobilizing an enzyme |
-
1983
- 1983-05-11 AU AU14445/83A patent/AU538170B2/en not_active Ceased
- 1983-05-27 GB GB08314851A patent/GB2127024B/en not_active Expired
- 1983-07-11 CA CA000432218A patent/CA1201990A/en not_active Expired
- 1983-07-19 IT IT48712/83A patent/IT1173739B/en active
- 1983-08-17 DE DE19833329624 patent/DE3329624A1/en active Granted
- 1983-08-24 JP JP58153373A patent/JPS5959188A/en active Pending
- 1983-09-14 BR BR8304970A patent/BR8304970A/en unknown
- 1983-09-14 FR FR8314648A patent/FR2532949B1/en not_active Expired
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2088880A (en) * | 1980-12-04 | 1982-06-16 | Owens Illinois Inc | Process for preparing semisynthetic proteins |
Also Published As
Publication number | Publication date |
---|---|
FR2532949B1 (en) | 1987-01-30 |
CA1201990A (en) | 1986-03-18 |
GB2127024B (en) | 1986-04-23 |
AU1444583A (en) | 1984-05-17 |
DE3329624C2 (en) | 1987-09-03 |
AU538170B2 (en) | 1984-08-02 |
GB8314851D0 (en) | 1983-07-06 |
FR2532949A1 (en) | 1984-03-16 |
BR8304970A (en) | 1984-04-24 |
IT8348712A0 (en) | 1983-07-19 |
JPS5959188A (en) | 1984-04-04 |
DE3329624A1 (en) | 1984-03-15 |
IT1173739B (en) | 1987-06-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Plummer Jr et al. | Human plasma carboxypeptidase N. Isolation and characterization. | |
Fernandez-Lafuente et al. | Hyperstabilization of a thermophilic esterase by multipoint covalent attachment | |
Janolino et al. | Catalytic effect of sulfhydryl oxidase on the formation of three-dimensional structure in chymotrypsinogen A | |
Fischer et al. | Purification and characterization of a thermotolerant beta-galactosidase from Thermomyces lanuginosus | |
US5554508A (en) | Process for the enzymatic synthesis of alkyl esters of peptides and peptides, and microparticles therefrom | |
GB2127024A (en) | Modified proteins and process for the production thereof | |
US4714676A (en) | Protein modification to provide enzyme activity | |
US4716116A (en) | Protein modification to provide enzyme activity | |
US4713335A (en) | Protein modification to provide enzyme activity | |
Soler et al. | Reactivation strategies by unfolding/refolding of chymotrypsin derivatives after inactivation by organic solvents | |
US4609625A (en) | Process for the production of modified proteins and product thereof | |
US4714677A (en) | Protein modification to provide enzyme activity | |
US4066504A (en) | Aliphatic dialdehyde-aromatic polyamine condensation products bound to proteins and enzymes | |
CA1200519A (en) | Process for the production and immobilization of modified proteins | |
Taipa et al. | Identification and characterization of Chromobacterium viscosum lipase | |
Guisán et al. | Immobilization-stabilization of thermolysin onto activated agarose gels | |
CA1200518A (en) | Process for preparing semisynthetic enzymes | |
Chen et al. | Improvement of cell lysis activity of immobilized lysozyme with reversibly soluble-insoluble polymer as carrier | |
Klemes et al. | Cross-linking preserves conformational changes induced in penicillinase by its substrates. | |
Shier | [19] Lectins as carriers: Preparation and purification of a concanavalin A—trypsin conjugate | |
Takahashi et al. | Affinity chromatography for purification of two urokinases from human urine | |
Basri et al. | Modification of lipase by polyethylene glycol | |
Saraswathi et al. | A systematic approach to induce new catalytic activities in proteins | |
Sasvári et al. | Crosslinking of glucoamylases via carbohydrates hardly affects catalysis but impairs stability | |
Wood et al. | an industrial catalyst |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PCNP | Patent ceased through non-payment of renewal fee |